ASTRAZENECA PLC reports

Company Names, identifiers, and filing context for this profile. 1 identity field
Company location
Cambridge
SEC filing record 1 source field available
Fiscal year end
31 December
ASTRAZENECA PLC has filed 2,050 SEC EDGAR filings since 13 Mar 1995

SEC filing history

Showing 351-375 of 1,000 matching filings.

Per page
25
Current page
15
SC TO-C

SC TO-C

Filing date
12 Dec 2023
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

FORM 6-K

Filing date
12 Dec 2023
Reporting date
12 Dec 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ASTRAZENECA TO ACQUIRE ICOSAVAX

Filing date
12 Dec 2023
Reporting date
12 Dec 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

BLOCK LISTING INTERIM REVIEW

Filing date
01 Dec 2023
Reporting date
01 Dec 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
01 Dec 2023
Reporting date
01 Dec 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

DISCONTINUATION OF TWO CRYSTALIZE EVIDENCE TRIALS

Filing date
01 Dec 2023
Reporting date
01 Dec 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

DIRECTOR/PDMR SHAREHOLDING

Filing date
24 Nov 2023
Reporting date
24 Nov 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TRUQAP APPROVED IN US FOR HR+ BREAST CANCER

Filing date
17 Nov 2023
Reporting date
17 Nov 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13D/A

SC 13D/A

Filing date
16 Nov 2023
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
25-NSE File 001-11960

25-NSE filing

Filing date
14 Nov 2023
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

UPDATE ON PACIFIC-2 PHASE III TRIAL FOR IMFINZI

Filing date
14 Nov 2023
Reporting date
14 Nov 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
144 File 001-11960

144 filing

Filing date
13 Nov 2023
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13D

SC 13D

Filing date
09 Nov 2023
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

DIRECTOR DECLARATION

Filing date
09 Nov 2023
Reporting date
09 Nov 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

IMFINZI COMBINATION IMPROVES PFS IN LIVER CANCER

Filing date
09 Nov 2023
Reporting date
09 Nov 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

AGREEMENT WITH ECCOGENE FOR CLINICAL STAGE GLP-1RA

Filing date
09 Nov 2023
Reporting date
09 Nov 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

9M AND Q3 2023 RESULTS

Filing date
09 Nov 2023
Reporting date
02 Nov 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
01 Nov 2023
Reporting date
01 Nov 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ASTRAZENECA CELL & GENE THERAPY DEAL W/ CELLECTIS

Filing date
01 Nov 2023
Reporting date
01 Nov 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ASTRAZENECA SETTLES NEXIUM LIABILITY LITIGATIONS

Filing date
03 Oct 2023
Reporting date
03 Oct 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
02 Oct 2023
Reporting date
02 Oct 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

DATO-DXD IMPROVED PFS IN BREAST CANCER

Filing date
25 Sep 2023
Reporting date
22 Sep 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ALEXION COMPLETES PFIZER GENE THERAPY AGREEMENT

Filing date
20 Sep 2023
Reporting date
20 Sep 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ENHERTU RECOMMENDED IN EU FOR HER2-MUTANT NSCLC

Filing date
15 Sep 2023
Reporting date
15 Sep 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

FASENRA PHASE III EGPA TRIAL MET PRIMARY ENDPOINT

Filing date
11 Sep 2023
Reporting date
11 Sep 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .